首页|疏肝解郁法治疗冠心病合并抑郁的Meta分析及GRADE评价

疏肝解郁法治疗冠心病合并抑郁的Meta分析及GRADE评价

扫码查看
目的:评价疏肝解郁法治疗冠心病合并抑郁的有效性和安全性。方法:计算机检索中文数据库中国生物医学文献服务系统、维普数据库、中国期刊全文数据库、万方数据库及英文数据库 PubMed、the Cochrane Library、Web of Science,检索时限为自建库至2022年 10月。对纳入的结局指标中医证候积分、有效率(心绞痛有效率、心电图有效率、抑郁有效率)、抑郁量表评分[抑郁症自评量表(SDS)、汉密尔顿抑郁量表(HAMD)]及 C-反应蛋白(CRP)进行 Meta分析,对中医证候积分、有效率、抑郁量表评分进行证据质量评价。结果:最终纳入符合标准的文献 22篇,涉及病人 1 828例。与西药常规治疗相比,联用疏肝解郁中药可降低病人的中医证候积分[SMD=-0。89,95%CI(-1。20,-0。58),P<0。000 01],提高心绞痛有效率[RR=1。29,95%CI(1。23,1。36),P<0。000 01]和心电图有效率[RR=1。21,95%CI(1。08,1。36),P =0。001],改善抑郁有效率[RR=1。50,95%CI(1。33,1。71),P<0。000 01],降低 HAMD评分[SMD=-2。17,95%CI(-2。90,-1。44),P<0。000 01]、SDS评分[SMD=-1。73,95%CI(-2。33,-1。13),P<0。000 01]及CRP水平[SMD=-1。81,95%CI(-2。06,-1。55),P<0。000 01],且无明显的药物不良反应。GRADE分级结果显示,中医证候积分的证据质量为极低级,心绞痛有效率和抑郁有效率为中级,心电图有效率、HAMD评分、SDS评分为低级。结论:现有证据表明,疏肝解郁法可有效改善冠心病合并抑郁病人的临床症状,且安全性较高。
Shugan Jieyu Therapy for the Treatment of Coronary Heart Disease with Depression:Meta-analysis and GRADE Evaluation
Objective:To evaluate the efficacy and safety of Shugan Jieyu therapy for the treatment of coronary heart disease complicated with depression.Methods:Computer retrieved datas from the self-built database up to October 2022.Chinese databases included Chinese Medical Literature Database,VIP database,Chinese Journal Full-text Database,WanFang Database.English databases included PubMed,the Cochrane Library and Web of Science.Meta-analysis was performed based on the included outcome indicators of traditional Chinese medicine(TCM)syndrome score,effective rate(angina pectoris effective rate,electrocardiogram effective rate,depression effective rate),depression scale score[Self-rating Depression Scale(SDS),Hamilton Depression Scale(HAMD)],and C-reactive protein(CRP).The evidence quality of TCM syndrome score,effective rate and depression scale score were evaluated.Results:A total of 22 literatures were included,involving 1 828 patients.Compared with conventional western medicine treatment,combined use of TCM for Shugan Jieyu could significantly reduce the TCM syndrome score of patients(SMD=-0.89,95%CI-1.20--0.58,P<0.000 01),improved the effective rate of angina pectoris(RR=1.29,95%CI 1.23-1.36,P<0.000 01)and ECG response rate(RR=1.21,95%CI 1.08-1.36,P =0.001),improved depression response rate(RR=1.50,95%CI 1.33-1.71,P<0.000 01),decreased HAMD score(SMD=-2.17,95%CI-2.90--1.44,P<0.000 01),SDS score(SMD=-1.73,95%CI-2.33--1.13,P<0.000 01)and CRP level(SMD=-1.81,95%CI-2.06--1.55,P<0.000 01),and there were no obvious adverse reactions.GRADE rating results showed that the evidence quality of TCM syndrome scores were low,the effective rate of angina pectoris and depression were moderate,and the effective rate of electrocardiogram,HAMD and SDS score were low.Conclusion:The existing evidence shows that the method of Shugan Jieyu therapy can effectively improve the clinical symptoms of patients with coronary heart disease complicated with depression,and with high safety.

coronary heart diseasedepressionShugan JieyuMeta-analysis

吴洋、王宇、李柏辰、王保福、王显

展开 >

北京中医药大学东直门医院(北京 100029)

河北医科大学第一医院

冠心病 抑郁 疏肝解郁 Meta分析

北京中医药大学"重点攻关"项目

2020-JYB-ZDGG-113

2024

中西医结合心脑血管病杂志
中国中西医结合学会 山西医科大学第一医院

中西医结合心脑血管病杂志

CSTPCD
影响因子:1.463
ISSN:1672-1349
年,卷(期):2024.22(9)
  • 48